Brazil's ANVISA Approves Drug Delivery via iFood, Rappi, and Mercado Livre Apps

The Quick Take

• Brazil's health regulator ANVISA has approved medication delivery through digital platforms including iFood, Rappi, and Mercado Livre.
• The resolution, published in the official gazette and based on a March 2026 law, allows licensed pharmacies to fulfil medicine orders via apps.
• The ruling creates a significant new revenue stream for app-based delivery platforms in Brazil's pharmaceutical sector.

Brazil's National Health Surveillance Agency (ANVISA) approved regulations enabling medication delivery through leading digital platforms including iFood, Rappi, and Mercado Livre on August 10, 2026. The resolution, published in the Diário Oficial da União and grounded in a March 2026 legislation, allows licensed pharmacies to partner with digital delivery platforms to fulfil over-the-counter and prescription medication orders — subject to applicable pharmaceutical dispensing rules. The decision integrates Brazil's pharmaceutical retail sector with its highly developed last-mile delivery infrastructure, which is among the most sophisticated in Latin America.

The regulatory approval creates material revenue opportunities for the three named platforms. iFood, Latin America's dominant food delivery app (owned by Prosus NV), Rappi (SoftBank-backed Colombian unicorn), and Mercado Livre (MELI, Nasdaq) each gain access to Brazil's US$18+ billion pharmaceutical retail market. Pharmacy chains including Raia Drogasil (RADL3.SA) and Ultragenyx-backed independents face a competitive disruption threat, as platform-aggregated delivery could erode foot traffic in traditional pharmacy models. The ruling mirrors similar digital pharmacy regulatory frameworks in the US (Amazon Pharmacy), Europe (DocMorris), and India (1MG/TATA Health).

The key forward development to watch is ANVISA's implementation timeline for prescription medication delivery — the current approval likely covers OTC products, with controlled substance delivery requiring additional regulatory scaffolding. Mercado Livre's MELI.US shares are the most directly investable beneficiary, followed by Prosus (PRX.AS) given its iFood ownership. Investors should monitor Brazil's pharmaceutical e-commerce penetration rate, currently estimated at under 3% of total pharmacy sales, as the regulatory unlock could accelerate digital pharmacy adoption to 8-10% within three years.

Synthesized from 2 sources.